Drug Profile
Research programme: enzyme-based Coeliac disease therapeutic - AMYRA Biotech
Alternative Names: Gluten-targeting enzymes - AMYRALatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AMYRA Biotech AG
- Class Enzymes
- Mechanism of Action Enzyme replacements; Gluten inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Coeliac disease in Switzerland (PO)
- 10 Apr 2014 Early research in Coeliac disease in Switzerland (PO)